• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

微小 RNA 在脂肪肝发病机制中的关键作用:新进展、挑战和潜在方向。

Critical Roles of microRNAs in the Pathogenesis of Fatty Liver: New Advances, Challenges, and Potential Directions.

机构信息

Department of Pharmacy, School of Life and Health Science, Anhui Science and Technology University, Fengyang, 233100, China.

State Key Laboratory of Tea Biochemistry and Biotechnology, School of Science and Technology of Tea and Food, Anhui Agricultural University, No. 130, Changjiang West Road, Hefei, 230036, Anhui, China.

出版信息

Biochem Genet. 2018 Oct;56(5):423-449. doi: 10.1007/s10528-018-9870-9. Epub 2018 Jun 27.

DOI:10.1007/s10528-018-9870-9
PMID:29951838
Abstract

In this review, we summarize the current understanding of microRNA (miRNA)-mediated modulation of the gene expression in the fatty liver as well as related signaling pathways. Because of the breadth and diversity of miRNAs, miRNAs may have a very wide variety of biological functions, and much evidence has confirmed that miRNAs are involved in the pathogenesis of fatty liver. In the pathophysiological mechanism of fatty liver, miRNAs may be regulated by upstream regulators, and have their own regulatory targets. miRNAs display important roles in the pathological mechanisms of alcoholic liver disease and non-alcoholic fatty liver disease. At present, most of the miRNA studies are focused on cell and tissue levels, and in vivo studies will help us elucidate the regulation of miRNAs and help us evaluate the potential of miRNAs as diagnostic markers and therapeutic targets. Furthermore, there is evidence that miRNAs are involved in the mechanism of natural medicine treatment in fatty liver. Given the important roles of miRNAs in the pathogenesis of fatty liver, we predict that studies of miRNAs in the pathogenesis of fatty liver will contribute to the elucidation of fatty liver pathology and the treatment of fatty liver patients.

摘要

在这篇综述中,我们总结了目前对 miRNA(microRNA)介导的肝脏脂肪变性基因表达调控及其相关信号通路的认识。由于 miRNA 的广泛性和多样性,miRNA 可能具有非常广泛的生物学功能,大量证据已经证实 miRNA 参与了脂肪肝的发病机制。在脂肪肝的病理生理机制中,miRNA 可能受到上游调控因子的调控,并具有自己的调控靶点。miRNA 在酒精性肝病和非酒精性脂肪性肝病的病理机制中发挥重要作用。目前,大多数 miRNA 研究都集中在细胞和组织水平,而体内研究将有助于我们阐明 miRNA 的调控作用,并有助于我们评估 miRNA 作为诊断标志物和治疗靶点的潜力。此外,有证据表明 miRNA 参与了脂肪肝的天然药物治疗机制。鉴于 miRNA 在脂肪肝发病机制中的重要作用,我们预测 miRNA 在脂肪肝发病机制中的研究将有助于阐明脂肪肝的病理学和脂肪肝患者的治疗。

相似文献

1
Critical Roles of microRNAs in the Pathogenesis of Fatty Liver: New Advances, Challenges, and Potential Directions.微小 RNA 在脂肪肝发病机制中的关键作用:新进展、挑战和潜在方向。
Biochem Genet. 2018 Oct;56(5):423-449. doi: 10.1007/s10528-018-9870-9. Epub 2018 Jun 27.
2
Role of microRNAs in alcohol-induced liver disorders and non-alcoholic fatty liver disease.微小 RNA 在酒精性肝疾病和非酒精性脂肪性肝病中的作用。
World J Gastroenterol. 2018 Sep 28;24(36):4104-4118. doi: 10.3748/wjg.v24.i36.4104.
3
Critical roles of microRNAs in the pathogenesis of systemic sclerosis: New advances, challenges and potential directions.微小RNA在系统性硬化症发病机制中的关键作用:新进展、挑战与潜在方向
Int Immunopharmacol. 2015 Sep;28(1):626-33. doi: 10.1016/j.intimp.2015.07.042. Epub 2015 Aug 1.
4
MicroRNAs as a Novel Tool in the Diagnosis of Liver Lipid Dysregulation and Fatty Liver Disease.微小 RNA 作为一种新型工具在肝脂质失调和脂肪肝疾病诊断中的应用。
Molecules. 2019 Jan 9;24(2):230. doi: 10.3390/molecules24020230.
5
A Series of microRNA in the Chromosome 14q32.2 Maternally Imprinted Region Related to Progression of Non-Alcoholic Fatty Liver Disease in a Mouse Model.14号染色体q32.2母系印记区域中的一系列微小RNA与小鼠模型中非酒精性脂肪性肝病进展相关
PLoS One. 2016 May 2;11(5):e0154676. doi: 10.1371/journal.pone.0154676. eCollection 2016.
6
MicroRNAs and liver disease.微小RNA与肝脏疾病
J Hum Genet. 2017 Jan;62(1):75-80. doi: 10.1038/jhg.2016.53. Epub 2016 May 26.
7
Integrative microRNA profiling in alcoholic hepatitis reveals a role for microRNA-182 in liver injury and inflammation.酒精性肝炎中整合的 microRNA 谱分析显示 microRNA-182 在肝损伤和炎症中的作用。
Gut. 2016 Sep;65(9):1535-45. doi: 10.1136/gutjnl-2015-311314. Epub 2016 May 10.
8
MicroRNAs as biomarkers and regulators of nonalcoholic fatty liver disease.微小RNA作为非酒精性脂肪性肝病的生物标志物和调节因子
J Dig Dis. 2016 Nov;17(11):708-715. doi: 10.1111/1751-2980.12408.
9
Circulating MicroRNAs as potential biomarkers for alcoholic steatohepatitis.循环 microRNAs 作为酒精性脂肪性肝炎的潜在生物标志物。
Liver Int. 2013 Sep;33(8):1257-65. doi: 10.1111/liv.12196. Epub 2013 May 20.
10
Expression of genes for microRNA-processing enzymes is altered in advanced non-alcoholic fatty liver disease.在晚期非酒精性脂肪性肝病中,microRNA 加工酶的基因表达发生改变。
J Gastroenterol Hepatol. 2013 Aug;28(8):1410-5. doi: 10.1111/jgh.12268.

引用本文的文献

1
Lack of associations of microRNAs with severe NAFLD in people living with HIV: discovery case-control study.在 HIV 感染者中,miRNAs 与严重非酒精性脂肪性肝病之间缺乏关联:发现病例对照研究。
Front Endocrinol (Lausanne). 2023 Sep 22;14:1230046. doi: 10.3389/fendo.2023.1230046. eCollection 2023.
2
Periodontal disease-related nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: An emerging concept of oral-liver axis.牙周病相关的非酒精性脂肪性肝病和非酒精性脂肪性肝炎:口腔-肝脏轴的一个新兴概念。
Periodontol 2000. 2021 Oct;87(1):204-240. doi: 10.1111/prd.12387.
3
Week 2020 Poster Presentations.
2020年第20周海报展示。
United European Gastroenterol J. 2020 Oct;8(8_suppl):144-887. doi: 10.1177/2050640620927345.
4
Circulating microRNA Associated to Different Stages of Liver Steatosis in Prader-Willi Syndrome and Non-Syndromic Obesity.与普拉德-威利综合征和非综合征性肥胖症肝脏脂肪变性不同阶段相关的循环微小RNA
J Clin Med. 2020 Apr 14;9(4):1123. doi: 10.3390/jcm9041123.
5
Detection of Serum miRNAs Affecting Liver Apoptosis in a Periodontitis Rat Model.检测牙周炎大鼠模型中影响肝脏细胞凋亡的血清微小 RNA。
In Vivo. 2020 Jan-Feb;34(1):117-123. doi: 10.21873/invivo.11752.
6
Nonalcoholic fatty liver disease in obese adolescents: the role of genetic polymorphisms.肥胖青少年的非酒精性脂肪性肝病:基因多态性的作用
Hepatobiliary Surg Nutr. 2019 Apr;8(2):179-180. doi: 10.21037/hbsn.2018.12.03.